UK management practices in stage i seminoma and the medical research council trial of imaging and schedule in seminoma testis managed with surveillance

Clinical Oncology

Volumn 24, Issue 1, 2012, Pages 25-29

  Cafferty, F H ^a   Gabe, R ^a   Huddart, R A ^b   Rustin, G ^c   Williams, M P ^d   Stenning, S P ^a   Bara, A ^a   Bathia, R ^a   Freeman, S C ^a   Alder, L ^e   Joffe, J K ^f  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d DERRIFORD HOSPITAL   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; EDITORIAL; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEMINOMA; TREND STUDY; UNITED KINGDOM;

GREAT BRITAIN; HUMANS; MALE; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEMINOMA; TESTICULAR NEOPLASMS; WATCHFUL WAITING;

EID: 84455161024     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.09.005     Document Type: Editorial

References (53)

1. Horwich A., Shipley J., Huddart R. Testicular germ-cell cancer. Lancet 2006, 367:754-765.
2. Steele G.S., Richie J.P., Stewart A.K., Menck H.R. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer 1999, 86:2171-2183.
3. Cancer Research UK. UK testicular cancer incidence statistics 2007 [5th April 2011]; Available at: http://info.cancerresearchuk.org/cancerstats/types/testis/incidence/index.htm.
4. Warde P., Specht L., Horwich A., et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002, 20:4448-4452.
5. Groll R.J., Warde P., Jewett M.A. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007, 64:182-197.
6. Mead G.M., Fossa S.D., Oliver R.T., et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 2011, 103:241-249.
7. Tandstad T., Smaaland R., Solberg A., et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol 2011, 29:719-725.
8. Schmoll H.J., Jordan K., Huddart R., et al. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20:iv83-iv88.
9. Krege S., Beyer J., Souchon R., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008, 53:478-496.
10. Motzer R.J., Agarwal N., Beard C., et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 2009, 7:672-693.
11. Management of adult testicular germ cell tumours (#124) 2011, Scottish Intercollegiate Guidelines Network, Available at: http://www.sign.ac.uk/pdf/sign124.pdf.
12. Albers P., Albrecht W., Algaba F., et al. European Association of Urology guidelines on testicular cancer 2011, Available at:http://www.uroweb.org/gls/pdf/10_Testicular_Cancer.pdf.
13. Improving outcomes in urological cancer - manual 2002, National Institute for Health and Clinical Excellence (NICE), [5th April 2011]; Available at:http://www.nice.org.uk/guidance/.
14. Chung P., Mayhew L.A., Warde P., Winquist E., Lukka H. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) 2010, 22:6-16.
15. Young A., Bhosle J., Joffe J., et al. Factors influencing adjuvant treatment choices in stage I seminoma: the patients perspective 2009, NCRI Cancer Conference, Birmingham.
16. Huddart R.A., Joffe J.K. Preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol) 2006, 18:693-695.
17. Travis L.B., Curtis R.E., Storm H., et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. JNatl Cancer Inst 1997, 89:1429-1439.
18. van den Belt-Dusebout A.W., de Wit R., Gietema J.A., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007, 25:4370-4378.
19. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97:1354-1365.
20. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003, 21:1513-1523.
21. Zagars G.K., Ballo M.T., Lee A.K., Strom S.S. Mortality after cure of testicular seminoma. J Clin Oncol 2004, 22:640-647.
22. Alomary I., Samant R., Genest P., Eapen L., Gallant V. The preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol) 2006, 18:696-699.
23. Kamba T., Kamoto T., Okubo K., et al. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol 2010, 17:980-987.
24. Kollmannsberger C., Tyldesley S., Moore C., et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011, 22:808-814.
25. Oliver R.T., Mason M.D., Mead G.M., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005, 366:293-300.
26. Oliver R.T., Mead G.M., Rustin G.J., et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011, 29:957-962.
27. Powles T., Robinson D., Shamash J., Moller H., Tranter N., Oliver T. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008, 19:443-447.
28. Skliarenko J., Vesprini D., Warde P. Stage I seminoma: what should a practicing uro-oncologist do in 2009?. Int J Urol 2009, 16:544-551.
29. Chung P., Warde P. Stage I seminoma: adjuvant treatment is effective but is it necessary?. J Natl Cancer Inst 2011, 103:194-196.
30. Cummins S., Yau T., Huddart R., Dearnaley D., Horwich A. Surveillance in stage I seminoma patients: a long-term assessment. Eur Urol 2009, 57:673-678.
31. Matakidou A., Mutsvangwa K., Ansell W., et al. Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group. Ann Oncol 2010, 21:1730-1731.
32. Aparicio J., Garcia dMX., Maroto P., et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003, 14:867-872.
33. Aparicio J., Germa J.R., Garcia dMX., et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. JClin Oncol 2005, 23:8717-8723.
34. Pectasides D., Pectasides E., Constantinidou A., Aravantinos G. Stage I testicular seminoma: management and controversies. Crit Rev Oncol Hematol 2009, 71:22-28.
35. Lawrentschuk N., Fleshner N.E. Therapeutic options following orchiectomy for stage I seminoma. Oncology 2009, 23:749-753.
36. Chung P.W., Daugaard G., Tyldesley S., et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol 2010, 28. abstract 4535.
37. Warde P., Gospodarowicz M. Evolving concepts in stage I seminoma. BJU Int 2009, 104:1357-1361.
38. Berrington D.G., Mahesh M., Kim K.P., et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009, 169:2071-2077.
39. Tarin T.V., Sonn G., Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. JUrol 2009, 181:627-632.
40. Smith-Bindman R., Lipson J., Marcus R., et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009, 169:2078-2086.
41. Davies H.E., Wathen C.G., Gleeson F.V. The risks of radiation exposure related to diagnostic imaging and how to minimise them. Br Med J 2011, 342:d947.
42. van Walraven C., Fergusson D., Earle C., et al. Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 2011, 29:2883-2888.
43. Chung P., Parker C., Panzarella T., et al. Surveillance in stage I testicular seminoma - risk of late relapse. Can J Urol 2002, 9:1637-1640.
44. Yoshida T., Kakimoto K., Takezawa K., et al. Surveillance following orchiectomy for stage I testicular seminoma: long-term outcome. Int J Urol 2009, 16:756-759.
45. Tolan S., Vesprini D., Jewett M.A., et al. No role for routine chest radiography in stage I seminoma surveillance. Eur Urol 2010, 57:474-479.
46. van As N.J., Gilbert D.C., Money-Kyrle J., et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008, 98:1894-1902.
47. Martin J.M., Panzarella T., Zwahlen D.R., Chung P., Warde P. Evidence-based guidelines for following stage 1 seminoma. Cancer 2007, 109:2248-2256.
48. Yu H.Y., Madison R.A., Setodji C.M., Saigal C.S. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009, 27:4327-4332.
49. Nathan P.D., Rustin G.R. The role of CT scanning in the surveillance of testicular tumours. Clin Oncol (R Coll Radiol) 2003, 15:121-122.
50. Fitzgerald R., Twiss D., Mehra R., Evans M., Qaiyum M., Collins M. Low-dose computed tomography surveillance of patients with testicular tumours. Clin Oncol (R Coll Radiol) 2004, 16:158.
51. Horwich A. Testicular cancer. Oncology: a multidisciplinary textbook 1995, 485-498. Chapman and Hall, London. A. Horwich (Ed.).
52. Krege S., Beyer J., Souchon R., et al. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: a Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 2008, 53:497-513.
53. Sohaib S.A., Koh D.M., Barbachano Y., et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 2009, 64:362-367.